New clinical evidence
Essentiale proven to be 2.5x more effective
First of its kind study
ESSENTIALE® WITH A GROUNDBREAKING STUDY DELIVERS COMPELLING, HIGHESTQUALITY CLINICAL EVIDENCE FOR MANAGING FATTY LIVER / METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE (MASLD).
Results
More effective in improving fatty liver compared to diet and exercise alone
Natural energy
Proven to reduce fatigue associated with fatty liver
Blood sugar level
By supporting liver health, it helps the body handle sugar more effectively
Sustains benefits
No rebound effect after discontinuation
No safety concerns
Well-tolerated option to support liver function and over all well-being
Overview
Study attributes
Placebo controlled & double blind
Evaluating the efficacy and safety of ESSENTIALE® while preventing bias & objective results
15 centers
Multi country approach
Background
Assessing Improvement in Quality of Life.
First of its kind study in the hepatoprotectors category assessing improvement in quality of life through a clinically validated questionnaire &, validated steatosis reduction through highest standard of test
Early intervention is key
References
- Stefan N, et al. Poster presented at: EASL SLD Summit; January 23rd – 25th, 2025; Estoril, Portugal. (Poster ID: PO7-01) https://easl.eu/wp-content/uploads/2025/01/EASL_SLD_Summit_2025-Abstract-book-FINAL.pdf
- Stefan N, et al. Poster presented at: AASLD; November 15th – 19th, 2024; San Diego, CA, USA. (Poster ID: 5037) https://www.aasld.org/sites/default/files/2024-11/TLM2024LBA_20241115A.pdf
"Placebo-controlled" means one study group receives the actual treatment, while another gets a placebo (an inactive look-alike). This helps researchers distinguish the treatment's real effects from the psychological impact of believing you're being treated.
"Double-blind" means that in a clinical study, neither participants nor researchers know who receives which treatment, preventing bias and ensuring objective results.